SS
FDMT icon

SBI Securities’s 4D Molecular Therapeutics FDMT Stock Holding History

SBI Securities’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$466 Hold
35
– – ﹤0.01% 3055
2026
Q1 		$326 Hold
35
– – ﹤0.01% 3045
2025
Q4 		$263 Sell
35
-1
-3% -$10 ﹤0.01% 3122
2025
Q3 		$313 Buy
36
+1
+3% +$6 ﹤0.01% 3166
2025
Q2 		$130 Hold
35
– – ﹤0.01% 3451
2025
Q1 		$113 Hold
35
– – ﹤0.01% 3403
2024
Q4 		$195 Buy
+35
New +$275 ﹤0.01% 3252

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

SBI Securities's FDMT Position: Q2 2026 in Review

SBI Securities held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 35 shares worth $466. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

SBI Securities first reported a position in FDMT in Q4 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • SBI Securities held 35 shares of 4D Molecular Therapeutics worth $466 as of Q2 2026.
  • SBI Securities left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3055 holding.
  • SBI Securities first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.